Glaucoma, Vision & Longevity: Supplements & Science podcast

Once Glaucoma Starts Progressing, How Hard Is It to Stop? A New 12-Year Study Gives an Answer

0:00
20:27
Manda indietro di 15 secondi
Manda avanti di 15 secondi

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/once-glaucoma-starts-progressing-how-hard-is-it-to-stop-a-new-12-year-study-gives-an-answer

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Once Glaucoma Starts Progressing, How Hard Is It to Stop? A New 12-Year Study Gives an Answer A first confirmed visual-field progression event is a warning—not a guarantee that vision will keep worsening. But a large, long-running study from Bascom Palmer Eye Institute suggests that a meaningful share of eyes do progress again, even while receiving routine care. Published online in JAMA Ophthalmology on October 22, 2026, the study found that recurrence was more likely when vision had been declining quickly before the first event and when average eye pressure remained higher afterward. More pressure reduction was associated with less recurrence, but this was an observational study: it cannot prove that treatment escalation caused the difference. () What the Bascom Palmer study measured Researchers reviewed records from 7,457 eyes belonging to 5,086 people with open-angle glaucoma or suspected glaucoma. The records spanned 1998 to 2025. Across the full group, average follow-up was 12.4 years, with an average of 12.3 visual-field tests per eye. A visual-field test measures how well a person sees in different parts of their field of vision. The first progression analysis included all 7,457 eyes. The recurrence analysis was narrower: 1,951 eyes had an initial “likely progression” event, but only 635 had enough later visual-field tests and eye-pressure records for the researchers to assess recurrence. The recurrence results therefore describe this smaller, well-monitored group—not every eye in the original registry. () How the study defined a progression event The researchers used Guided Progression Analysis, a tool for comparing visual-field test results over time. It compares later tests with the average of the first two reliable tests and looks for worsening at the same test locations beyond the amount expected from normal test-to-test variation. An eye met the study’s definition of “likely progression” when three or more of the same locations worsened on three consecutive examinations. The event was dated to the first of those three examinations. This is a repeatable, computer-based signal—not a guarantee that every flagged change represents irreversible glaucoma damage without any possible test or eye-health influence. () To look for a second event, the researchers reset the comparison: the first progressing visual field and the next examination became the new baseline tests. They then reapplied the same progression rule to the remaining tests. The recurrence analysis required at least four visual-field tests after the first progressing examination. () How often did progression recur? Across the full cohort, 1,951 of 7,457 eyes—26.2%—had an initial likely-progression event. Among the 635 eyes with enough subsequent testing and pressure data, 167—26.3%—had a recurrent event during the follow-up available to the study. () The researchers also used a time-to-event method that accounts for eyes having different lengths of follow-up. Its estimated cumulative recurrence was: For the full table, please open this article on visualfieldtest.com. At the 3-year mark, the 95% confidence interval was 11.6% to 17.1%; at 5 years, it was 22.1% to 29.5%; and at 10 years, it was 35.8% to 52.1%. The number at risk fell from 635 at the start to 30 at 10 years; it was 578 at 2 years, 382 at 4 years, 151 at 6 years, and 45 at 8 years. The 10-year estimate is therefore much less precise than the earlier estimates. () These numbers are not contradictory: 26.3% is the share of the 635 eyes with a recurrence recorded during their available follow-up. The 43.5% figure is the estimated cumulative chance by 10 years, accounting for differences in follow-up time. It does not mean that 43.5% of all 7,457 eyes recurred. The paper also notes that recurrence was recorded more often in the 635-eye analysis than in the broader group of eyes with initial progression—26.3% versus 15.2%—in part because eyes without enough later tests could not register a recurrence. () Which eyes were more likely to progress again? The strongest signal was how quickly the visual field had already been worsening. In the study’s adjusted analysis, each 1-decibel-per-year faster loss in mean deviation—a summary measure of visual-field damage—was associated with a 73% higher hazard of recurrence. “Hazard” describes the relative rate of a new event over time; it is not the same as an individual’s absolute probability of recurrence. () Other adjusted associations included: Higher average eye pressure after the first event: each additional 1 millimeter of mercury was associated with a 9% higher recurrence hazard. Greater pressure reduction: each additional 10% of reduction from the pre-event average was associated with an 11% lower hazard. The pressure level and percentage reduction were analyzed in separate models because they were related; they should not be added together as if they were independent effects. Older age: each additional five years was associated with roughly an 8% to 11% higher hazard, depending on the model. Visual-field damage at the first event: eyes with a less negative mean-deviation score—generally less advanced loss—had a higher measured recurrence hazard. The authors cautioned that progression can be harder to detect in advanced disease because damaged test locations have less remaining range to worsen. () The study’s combined prediction model had moderate, not high, ability to distinguish which eyes would recur. It is a useful risk signal, not a validated calculator for an individual patient. () Fast progressors stood out Among 96 eyes losing more than 1 decibel per year before the first event, 42.7% had recurrent progression, compared with 23.4% of slower-progressing eyes. The difference was about 19 percentage points. () This does not mean that every fast-progressing eye will worsen again, or that every slower-progressing eye is safe. It does mean that the earlier rate of change contains important information: a first progression event in an eye that was already losing field quickly deserves particular attention. What happened to fast-progressing eyes after the first event? The study compared the change in mean-deviation slope for fast-progressing eyes that did and did not have a recorded recurrence: Fast progressors without a recorded recurrence slowed from about −1.71 to −0.39 decibels per year after the first event. Fast progressors with recurrence slowed less, from about −1.70 to −1.31 decibels per year. The groups’ pre-event slopes were nearly identical. Afterward, the nonrecurrence group had a lower average pressure—14.0 versus 16.2 millimeters of mercury—and a pressure reduction greater than 20% was more common among them, 36.4% versus 12.2%. These are striking observations, but they do not establish why the groups’ courses diverged. () Does this show that stronger pressure lowering changed the disease course? It is consistent with that possibility, but it is not proof. Pressure lowering is already supported by randomized trials as a way to reduce glaucoma progression. In the Bascom Palmer study, recurrence was also associated with higher post-event pressure, and eyes with a larger pressure reduction tended to fare better. But the study did not randomly assign people to different pressure targets or treatment plans. () Several other explanations could contribute: Regression to the mean: an eye selected because it had a particularly steep prior decline or a triggering progression event may show a less extreme slope later, even without an effective treatment change. This is especially relevant when comparing a very fast pre-event period with the period afterward. Treatment-selection bias: clinicians may intensify treatment for eyes thought to be at greatest risk. In observational data, treatment and disease severity are intertwined, and the direction of the resulting bias is not predictable. Unknown treatment and adherence: the investigators did not have records of medication changes, laser treatment, surgery, or how consistently treatment was used. A lower recorded pressure could reflect any mix of treatment changes, improved adherence, or ordinary variation. Selection and follow-up: only 635 of the 1,951 eyes with initial progression had the post-event tests and pressure data needed for this analysis. Eyes that remain in care and receive more tests also have more opportunity for another event to be detected. Long-term estimates depend on assumptions about eyes that leave follow-up. () So the study supports a clinically plausible message—pressure reduction may help after progression is detected—but it does not show that a particular escalation caused the slowing seen in one subgroup. What does the pressure after the event tell us? The proportion of eyes with a recorded recurrence rose across the study’s categories of average post-event pressure: For the full table, please open this article on visualfieldtest.com. These are crude recurrence proportions by pressure category, not proof of a safe cutoff or a guarantee that a particular pressure prevents damage. The analysis found a graded association, but some eyes still progressed even when their recorded average was 12 millimeters of mercury o

Support the show

Altri episodi di "Glaucoma, Vision & Longevity: Supplements & Science"